Trade-Ideas LLC identified

Endo International

(

ENDP

) as a pre-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Endo International as such a stock due to the following factors:

  • ENDP has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $150.1 million.
  • ENDP traded 17,443 shares today in the pre-market hours as of 9:12 AM.
  • ENDP is up 3.7% today from yesterday's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ENDP with the Ticky from Trade-Ideas. See the FREE profile for ENDP NOW at Trade-Ideas

More details on ENDP:

Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. ENDP has a PE ratio of 5. Currently there are 6 analysts that rate Endo International a buy, 1 analyst rates it a sell, and 10 rate it a hold.

The average volume for Endo International has been 10.1 million shares per day over the past 30 days. Endo International has a market cap of $3.4 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.33 and a short float of 3.1% with 0.96 days to cover. Shares are down 75% year-to-date as of the close of trading on Wednesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Endo International as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.

Highlights from the ratings report include:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Pharmaceuticals industry. The net income has significantly decreased by 76.8% when compared to the same quarter one year ago, falling from -$75.72 million to -$133.87 million.
  • The debt-to-equity ratio of 1.45 is relatively high when compared with the industry average, suggesting a need for better debt level management. Along with the unfavorable debt-to-equity ratio, ENDP maintains a poor quick ratio of 0.74, which illustrates the inability to avoid short-term cash problems.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, ENDO INTERNATIONAL PLC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 82.22%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 147.05% compared to the year-earlier quarter. Turning toward the future, the fact that the stock has come down in price over the past year should not necessarily be interpreted as a negative; it could be one of the factors that may help make the stock attractive down the road. Right now, however, we believe that it is too soon to buy.
  • ENDO INTERNATIONAL PLC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has reported a trend of declining earnings per share over the past year. However, the consensus estimate suggests that this trend should reverse in the coming year. During the past fiscal year, ENDO INTERNATIONAL PLC swung to a loss, reporting -$1.51 versus $0.31 in the prior year. This year, the market expects an improvement in earnings ($4.59 versus -$1.51).

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.